Literature DB >> 9774222

Central administration of dopamine D3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding.

A Ekman1, H Nissbrandt, M Heilig, D Dijkstra, E Eriksson.   

Abstract

A 15-mer, all-phosphorothioate-modified antisense oligodeoxynucleotide (ASO) targeted against rat dopamine D3 receptor mRNA (4 microM, 5 days) significantly reduced (28%) the amount of binding sites labelled with [3H]spiperone in monolayer cultured Chinese hamster ovary (CHO) cells transfected with the complementary desoxyribonucleic acid (cDNA) for the rat D3 receptor. In contrast, D3-ASO treatment did not reduce the amount of bound [3H]spiperone in CHO cells transfected with D2 receptor cDNA. Intracerebroventricular infusion of D3-ASO (osmotic minipump, 10 microg/microl/h, 7 days) influenced dopamine receptor density in the limbic forebrain such that the upper part of the dopamine/[3H]spiperone displacement curve--tentatively representing the D3 receptor--was altered significantly. Spontaneous locomotor activity of non-habituated rats was increased significantly in D3-ASO-treated animals; in addition, in vivo microdialysis revealed a moderate increase in dopamine release in the nucleus accumbens in these animals. In all experiments, an oligodeoxynucleotide comprising the same nucleotides as the antisense sequence, but in random order, was used as control. It is concluded that the antisense strategy is useful for investigating the functional role of dopamine D3 receptors and that the dopamine D3 receptor is involved in rat locomotor behaviour.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774222     DOI: 10.1007/pl00005263

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  8 in total

1.  C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.

Authors:  R K McNamara; B Levant; B Taylor; R Ahlbrand; Y Liu; J R Sullivan; K Stanford; N M Richtand
Journal:  Neuroscience       Date:  2006-08-28       Impact factor: 3.590

2.  Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.

Authors:  Neil M Richtand; Benjamin Taylor; Jeffrey A Welge; Rebecca Ahlbrand; Michelle M Ostrander; Jeffrey Burr; Scott Hayes; Lique M Coolen; Laurel M Pritchard; Aaron Logue; James P Herman; Robert K McNamara
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

Review 3.  Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function.

Authors:  Neil M Richtand
Journal:  Neuropsychopharmacology       Date:  2006-07-19       Impact factor: 7.853

4.  Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine.

Authors:  Robert K McNamara; Aaron Logue; Kevin Stanford; Ming Xu; Jianhua Zhang; Neil M Richtand
Journal:  Synapse       Date:  2006-10       Impact factor: 2.562

Review 5.  Dopamine genes and attention-deficit hyperactivity disorder: a review.

Authors:  Salvatore DiMaio; Nathalie Grizenko; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

6.  Divergent effect of the selective D3 receptor agonist pd-128,907 on locomotor activity in Roman high- and low-avoidance rats: relationship to NGFI-A gene expression in the Calleja islands.

Authors:  Marc Guitart-Masip; Björn Johansson; Albert Fernández-Teruel; Adolf Tobeña; Lydia Giménez-Llort
Journal:  Psychopharmacology (Berl)       Date:  2007-10-19       Impact factor: 4.530

7.  Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia.

Authors:  Xue Sun; Hong-yan Gou; Fei Li; Guan-yi Lu; Rui Song; Ri-fang Yang; Ning Wu; Rui-bin Su; Bin Cong; Jin Li
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

8.  The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.

Authors:  Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.